CHRS, US19249H1032

Coherus Oncology stock trades 61.45 percent below its 52-week high

Published on 10/24/2026 at 21:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coherus Oncology had a USD 156.0 million market value on October 23, 2026. Coherus Oncology stock last stood at EUR 0.90 on October 23, 2026 at 9:56 p.m. CEST, down 2.82 percent versus the Stuttgart close.

Price range and business figures

Coherus Oncology stock stood 61.45 percent below its USD 2.62 52-week high on October 23, 2026.
Second-quarter 2026 revenue reached USD 14.31 million, up 39.53 percent year over year.
Coherus Oncology stock last stood at EUR 0.90 at Stuttgart on October 23, 2026 at 9:56 p.m. CEST, down 2.82 percent versus the prior close.
Market capitalization was USD 156.0 million on October 23, 2026.

CHRS, US19249H1032, Illustration mit AI erstellt.

Coherus Oncology stock was USD 1.01 on Nasdaq at 4:00 p.m. ET on October 23, 2026, 61.45 percent below its USD 2.62 52-week high. The company had a market capitalization of USD 156.0 million on the same date. Coherus Oncology stock last stood at EUR 0.90 on Stuttgart at 9:56 p.m. CEST on October 23, 2026, down 2.82 percent from the EUR 0.92 close of October 22, 2026.

Revenue reached USD 14.31 million

Coherus reported second-quarter 2026 revenue of USD 14.31 million, an increase of 39.53 percent from the same period a year earlier, according to Quiver Quantitative. The figure gives the stock a concrete operating reference while the market value remains below USD 160.0 million.

Stock remains below its yearly high

The primary Nasdaq quote was USD 1.01 on October 23, 2026, compared with a 52-week range of USD 0.94 to USD 2.62. Coherus therefore traded USD 1.61 below the upper end of that range. The stock's year-to-date performance was minus 18.85 percent, while volume reached 641,449 shares on October 23, 2026.

Pipeline supports the business case

Coherus describes itself as a commercial-stage oncology company with the approved PD-1 inhibitor LOQTORZI and clinical candidates including tagmokitug and casdozokitug. Its investor materials say tagmokitug is in Phase 1b studies and casdozokitug is being evaluated in a Phase 2 study, according to Coherus Oncology.

Comparison with peers

Coherus Oncology: down 3.81 percent on Nasdaq, market capitalization USD 156.0 million. Iovance Biotherapeutics: down 0.35 percent on Nasdaq, market capitalization USD 6.4 billion. Immunovant: down 2.37 percent on Nasdaq, market capitalization USD 5.9 billion.

Price position and investor perspective

The euro quotation placed Coherus at EUR 0.90 on Stuttgart on October 23, 2026 at 9:56 p.m. CEST, versus EUR 0.92 on October 22, 2026. The combination of USD 14.31 million in second-quarter revenue and a USD 156.0 million market value keeps operating progress and financing capacity central to the stock's valuation.

Market context: Market report S&P 500.